Biocon Expects US Success For Biosimilar Trastuzumab Despite Amgen Launch
Executive Summary
Leading Indian biologics firm Biocon reported first-quarter net profit soared more than 70% and said it is confident of a “very successful” US biosimilar trastuzumab launch, despite rival Amgen stealing a march by commercializing its own version first in the world’s largest drug market.
You may also be interested in...
Biocon’s Malaysia Insulin Plant Wins EU Clearance, Company Is Open To PE Investment
Biocon has received European regulatory clearance for its new Malaysian insulin plant and also said it is open to private-equity investment proposals for its fast-growing biologics division ahead of a planned IPO.
Mylan-Biocon’s Ogivri First Off Block In Australia But Competition In Sight
Mylan-Biocon’s biosimilar Herceptin debuts in Australia, promising to provide patients a high quality and affordable alternative, though at least three competing trastuzumab versions including Amgen’s Kanjinti are in the wings.
Mylan-Biocon’s Ogivri First Off Block In Australia But Competition In Sight
Mylan-Biocon’s biosimilar Herceptin debuts in Australia, promising to provide patients a high quality and affordable alternative, though at least three competing trastuzumab versions including Amgen’s Kanjinti are in the wings.